Maravai LifeSciences Holdings, Inc. (MRVI) has a MoatMap StockRank of 61/100 based on Quality (33/100), Value (41/100), and Momentum (72/100) factor scores. The current signal is HOLD. Maravai LifeSciences Holdings, a US life sciences raw materials and services provider. While it could theoretically benefit from 'Resilient Supply Chains' in pharma, its low quality score (Q:30) is a significant red flag against the Terry Smith lens for a quality compounder. Lacking deeper intelligence, this score suggests it does not meet the high bar for conviction.
Maravai LifeSciences Holdings, Inc. is a leading provider of critical nucleic acid synthesis products and biologics safety testing services essential for the development of vaccines, novel therapies, and diagnostics. The company maintains a strong competitive moat through its highly specialized expertise, proprietary technologies, and stringent quality control, serving top biopharmaceutical and academic clients. Maravai is a key enabler in the rapidly expanding fields of mRNA therapeutics, gene editing, and cell therapies, benefiting from high regulatory barriers and deep customer integration.
| Price | $4.64 |
| Market Cap | $1.7B |
| P/E (Forward) | -42.21 |
| Price/Book | 3.05 |
| Return on Equity | -41.0% |
| Return on Invested Capital | -28.7% |
| Debt/Equity | 85.36 |
| Gross Margin | 30.1% |
| Operating Margin | 1.1% |
| Revenue Growth | 40.5% |
| Free Cash Flow | $-11M |
Maravai LifeSciences Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).